

1. C de Jonge, JW Greve, N Bouvy, et al, EndoBarrier Gastrointestinal Liner treatment rapidly improves diabetes parameters paralleled by increased postprandial GLP-1 and PYY levels in obese type 2 diabetic patients, Department of Surgery, Maastricht University Medical Centre, presented at IFSO 2011, Hamburg, Germany.
2. Moura, GHD, et al, One Year Results of an Endoscopic, Duodenal-jejunal Exclusion Device for Weight Loss and Control of Type 2 Diabetes. Hospital das Clinicas, University of São Paulo, São Paulo, Brazil. DT&T, February 2012, vol 14, no.2:183-189.
3. Escalona, A., et al, "Weight Loss and Metabolic Improvement in Morbidly Obese Subjects Implanted for 1 Year With an Endoscopic Duodenal-jejunal Bypass Liner." Department of Digestive Surgery. Faculty of Medicine Pontificia Universidad Católica de Chile. Annals of Surgery, June 2012, Vol 255, Issue 6, p 1080-1085.
4. Unpublished data, Ricardo Cohen, MD, Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil.



EUROPE
GI Dynamics Europe
Prinzenallee 7
40549 Dusseldorf
Germany
+49 211 5239 1572

Customer Service Representative
HealthLink Europe B.V.
Centaurusweg 123
5015 TC Tilburg
The Netherlands
Tel: +31 13 5479337

UNITED STATES
GI Dynamics, Inc.
One Maguire Road
Lexington, MA 02421
USA

www.endobarrier.com

EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months and is CE marked.
EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States.
EndoBarrier is a registered trademark of GI Dynamics, Inc.
©2013 GI Dynamics, Inc. All rights reserved

The First Non-Surgical, Non-Pharmaceutical Solution for Treating Type 2 Diabetes and Obesity

Now You Can

Help Your Patients Regain Control of Their Type 2 Diabetes and Lose Weight at the Same Time

The Dual Challenge

Type 2 diabetes and obesity are increasing at epidemic proportions. Despite the need for clinical intervention, current therapies do not provide an optimal solution for either condition.

- Medications must be taken compliantly, can cause side effects and have diminishing efficacy
- Surgery can permanently alter patient anatomy and involve procedural risks and complications

In order to overcome these limitations, an entirely new approach must be taken.

Introducing EndoBarrier® Therapy

EndoBarrier Therapy is a new approach to treating type 2 diabetes and/or obesity that doesn't involve surgery or rely on medications to achieve its results. It is a safe, convenient and discreet treatment option for patients whose diabetes medications are no longer effective, who are at risk of health complications from their diabetes and/or weight who want to avoid surgery or the progression to daily insulin injections.

Clinical trial results demonstrate:

- Rapid reduction of blood sugar levels
- Weight loss of approximately 20 percent in 12 months

Now with EndoBarrier Therapy, practitioners can offer their patients a new option that may set them on the path to better health.

Indicated for a Broad Patient Population

- Type 2 diabetes
- BMI 30 - 45
- Tried and failed to control their diabetes or lose weight with drugs and/or lifestyle changes
- Over 18 years of age
- Not pregnant or planning to become pregnant



Discover

A Breakthrough in the Treatment of Type 2 Diabetes and/or Obesity

An Innovative Solution

EndoBarrier Therapy represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. In clinical studies, it has been shown to lower blood glucose levels and reduce weight in patients unable to reach their therapeutic goals with conventional drug therapies or lifestyle changes.

How EndoBarrier Works


The EndoBarrier liner creates a physical barrier between ingested food and the duodenum/proximal jejunum.

Clinical data suggest that EndoBarrier Therapy works by affecting key hormone levels involved in insulin sensitivity, glucose metabolism and satiety.¹




Compelling Clinical Results*

In clinical studies, more than 80 percent of patients were able to reach healthy blood glucose levels ($\text{HbA1c} \leq 7\%$) and lose an average 20 percent of their total body weight in one year.^{2,3,4}




87% of patients achieved healthy HbA1c level ($\leq 7\%$) by 9 months.



Patients lost an average 18% of their total body weight within 9 months.

Post-removal Experience*

Studies show that during the six-month period following EndoBarrier removal, patients experienced only a slight increase in HbA1c levels and maintained on average 75% of their achieved weight loss. In both studies, results were obtained without the support of a formal healthcare-directed diet or exercise program.^{2,3}



* Not included in *Instructions for Use*

Multidisciplinary Approach to Patient Care

EndoBarrier Therapy is offered at EndoBarrier Treatment Centres with the clinical expertise, training, and resources to best manage EndoBarrier patients throughout their treatment. Treatment is optimised through a multidisciplinary approach involving nutritional and behavioural counseling, exercise guidance, diabetes management, a specially-trained endoscopy team and the patient's primary care physician.

Learn more about referring your patients for EndoBarrier Therapy to the EndoBarrier Treatment Centre nearest you.

Visit www.endobarrier.com/find-doctor.

Diabetes Control Weight Loss
endobarrier®

"Since having the EndoBarrier placed eight weeks ago, I've lost 30 pounds, my diabetes has improved, and I've been able to reduce use of my diabetes medicines; but more importantly, I am active again."

Jenny Clarke, EndoBarrier patient treated at the National Obesity Surgery Centre, Manchester, UK.

"EndoBarrier Therapy results are clinically impressive with regard to glycemic control, medication reduction and weight loss. This therapy has become a cornerstone of my practice."

Alex Escalona, MD, Asst. Professor, Department of Digestive Surgery, Pontificia Universidad Católica de Chile, Santiago, Chile.

"EndoBarrier Therapy is an important, effective treatment for type 2 diabetes and obesity because it improves diabetes, usually within days, and is followed by substantial weight loss."

Carel le Roux, MRCP, Ph.D., FRCP, metabolic physician at Imperial College, London, UK.

